Literature DB >> 23996729

Facelift approach for mandibular resection and reconstruction.

Bernardo Bianchi1, Andrea Ferri, Silvano Ferrari, Chiara Copelli, Enrico Sesenna.   

Abstract

BACKGROUND: Mandibular resection is the mainstay in the treatment of several pathologies involving the jaw. When benign lesions are approached, a limited exposure and less invasive access considering the cosmetic outcome is desirable to reduce morbidity and increase patient's quality of life after surgery. The facelift approach is widely used for rhytidectomy, parotidectomy, and facial animation procedures, whereas its use for mandibular resection and reconstruction is not described yet.
METHODS: Six patients underwent mandibular resection and reconstruction with free flaps or bone grafts via the facelift approach were retrospectively evaluated with regard to function and cosmesis.
RESULTS: No impairment of occlusion or facial nerve occurred; mouth opening was normal in 4 patient and partially limited in 2. Cosmesis was assessed as excellent by 3 patients and good in 3.
CONCLUSION: The facelift approach is a valid option for resecting and reconstructing benign lesions involving the mandibular ramus, angle, and posterior body.
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  face lift; facial reconstruction; mandibular reconstruction; mandibular resections; mandibular tumor

Mesh:

Year:  2013        PMID: 23996729     DOI: 10.1002/hed.23484

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  2 in total

1.  The Role of Virtual Surgical Planning in the Era of Robotic Surgery.

Authors:  Jae Young Kim; Won Shik Kim; Eun Chang Choi; Woong Nam
Journal:  Yonsei Med J       Date:  2016-01       Impact factor: 2.759

2.  Modified facelift approach for posterior segmental mandibulectomy: a blend of oncology and cosmesis.

Authors:  Vishal Rao; Anand Subash; Piyush Sinha; Rachana Prasad; Kinjal Majumdar; Prasanth Puranik
Journal:  Eur Arch Otorhinolaryngol       Date:  2020-01-16       Impact factor: 2.503

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.